HomeCompareNVRO vs CL

NVRO vs CL: Dividend Comparison 2026

NVRO yields 34.25% · CL yields 2.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NVRO wins by $127.6K in total portfolio value
10 years
NVRO
NVRO
● Live price
34.25%
Share price
$5.84
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$168.6K
Annual income
$25,000.88
Full NVRO calculator →
CL
CL
● Live price
2.44%
Share price
$85.23
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.0K
Annual income
$5,451.69
Full CL calculator →

Portfolio growth — NVRO vs CL

📍 NVRO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNVROCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NVRO + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NVRO pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NVRO
Annual income on $10K today (after 15% tax)
$2,910.96/yr
After 10yr DRIP, annual income (after tax)
$21,250.75/yr
CL
Annual income on $10K today (after 15% tax)
$207.44/yr
After 10yr DRIP, annual income (after tax)
$4,633.94/yr
At 15% tax rate, NVRO beats the other by $16,616.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NVRO + CL for your $10,000?

NVRO: 50%CL: 50%
100% CL50/50100% NVRO
Portfolio after 10yr
$104.8K
Annual income
$15,226.29/yr
Blended yield
14.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

NVRO
Analyst Ratings
9
Buy
19
Hold
4
Sell
Consensus: Hold
Price Target
$30.32
+419.2% upside vs current
Range: $4.00 — $125.00
Altman Z
-0.6
Piotroski
2/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+8.5% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NVRO buys
0
CL buys
0
No recent congressional trades found for NVRO or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNVROCL
Forward yield34.25%2.44%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$168.6K$41.0K
Annual income after 10y$25,000.88$5,451.69
Total dividends collected$120.7K$18.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldHold
Analyst price target$30.32$92.45

Year-by-year: NVRO vs CL ($10,000, DRIP)

YearNVRO PortfolioNVRO Income/yrCL PortfolioCL Income/yrGap
1← crossover$14,125$3,424.66$11,014$313.84+$3.1KNVRO
2$19,634$4,520.76$12,200$415.44+$7.4KNVRO
3$26,882$5,873.02$13,607$553.09+$13.3KNVRO
4$36,278$7,514.85$15,301$741.41+$21.0KNVRO
5$48,296$9,478.22$17,374$1,002.00+$30.9KNVRO
6$63,469$11,792.55$19,958$1,367.44+$43.5KNVRO
7$82,395$14,483.60$23,243$1,887.87+$59.2KNVRO
8$105,736$17,572.52$27,512$2,642.43+$78.2KNVRO
9$134,212$21,075.04$33,197$3,759.22+$101.0KNVRO
10$168,608$25,000.88$40,973$5,451.69+$127.6KNVRO

NVRO vs CL: Complete Analysis 2026

NVROStock

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.

Full NVRO Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this NVRO vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NVRO vs SCHDNVRO vs JEPINVRO vs ONVRO vs KONVRO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.